日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細

  Neurodevelopmental Disorders Caused by De Novo Variants in KCNB1 Genotypes and Phenotypes

De Kovel, C. G. F., Syrbe, S., Brilstra, E. H., Verbeek, N., Kerr, B., Dubbs, H., Bayat, A., Desai, S., Naidu, S., Srivastava, S., Cagaylan, H., Yis, U., Saunders, C., Rook, M., Plugge, S., Muhle, H., Afawi, Z., Klein, K. M., Jayaraman, V., Rajagopalan, R., Goldberg, E., Marsh, E., Kessler, S., Bergqvist, C., Conlin, L. K., Krok, B. L., Thiffault, I., Pendziwiat, M., Helbig, I., Polster, T., Borggraefe, I., Lemke, J. R., Van den Boogaardt, M. J., Moller, R. S., & Koeleman, B. P. C. (2017). Neurodevelopmental Disorders Caused by De Novo Variants in KCNB1 Genotypes and Phenotypes. JAMA Neurology, 74(10), 1228-1236. doi:10.1001/jamaneurol.2017.1714.

Item is

基本情報

表示: 非表示:
資料種別: 学術論文

ファイル

表示: ファイル
非表示: ファイル
:
DeKovel_etal_2017a.pdf (出版社版), 2MB
ファイルのパーマリンク:
https://hdl.handle.net/11858/00-001M-0000-002E-17AD-C
ファイル名:
DeKovel_etal_2017a.pdf
説明:
-
OA-Status:
閲覧制限:
公開
MIMEタイプ / チェックサム:
application/pdf / [MD5]
技術的なメタデータ:
著作権日付:
-
著作権情報:
-
CCライセンス:
-

関連URL

表示:

作成者

表示:
非表示:
 作成者:
De Kovel, Carolien G. F.1, 2, 著者           
Syrbe, S.3, 著者
Brilstra, E. H.2, 著者
Verbeek, N.2, 著者
Kerr, B.4, 5, 6, 著者
Dubbs, H.7, 著者
Bayat, A.8, 著者
Desai, S.9, 著者
Naidu, S.10, 11, 著者
Srivastava, S.12, 著者
Cagaylan, H.13, 著者
Yis, U.14, 著者
Saunders, C.15, 16, 17, 著者
Rook, M.18, 著者
Plugge, S.19, 著者
Muhle, H.20, 著者
Afawi, Z.21, 著者
Klein, K. M.22, 著者
Jayaraman, V.23, 著者
Rajagopalan, R.23, 著者
Goldberg, E.7, 著者Marsh, E.7, 著者Kessler, S.7, 著者Bergqvist, C.7, 著者Conlin, L. K.23, 著者Krok, B. L.23, 著者Thiffault, I.15, 16, 著者Pendziwiat, M.20, 著者Helbig, I.7, 24, 著者Polster, T.25, 著者Borggraefe, I.26, 著者Lemke, J. R.27, 著者Van den Boogaardt, M. J.2, 著者Moller, R. S.28, 29, 著者Koeleman, B. P. C.2, 著者 全て表示
所属:
1Language and Genetics Department, MPI for Psycholinguistics, Max Planck Society, ou_792549              
2Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands, ou_persistent22              
3Division of Child Neurology and Inherited Metabolic Diseases, Department of General Pediatrics, Center for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany, ou_persistent22              
4Institute of Evolution, Systems and Genomics, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK, ou_persistent22              
5Manchester Centre For Genomic Medicine, Central Manchester University Hospitals National Health Service Foundation Trust, Manchester, UK, ou_persistent22              
6Manchester Academic Health Science Centre, Manchester, UK, ou_persistent22              
7Division of Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA, ou_persistent22              
8Department of Pediatrics, University Hospital of Hvidovre, Copenhagen, Denmark, ou_persistent22              
9Department of Neurogenetics, Kennedy Krieger Institute, Baltimore, MD, USA, ou_persistent22              
10Department of Neurology and Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA, ou_persistent22              
11Hugo Moser Research Institute, Kennedy Krieger Institute, Baltimore, MD, USA, ou_persistent22              
12Department of Neurology, Boston Children's Hospital, Boson, MA, USA, ou_persistent22              
13Department of Molecular Biology and Genetics, Bogaziçi University, Istanbul, Turkey, ou_persistent22              
14Division of Child Neurology, Department of Pediatrics, School of Medicine, Dokuz Eylül University, İzmir, Turkey, ou_persistent22              
15Center for Pediatric Genomic Medicine, Department of Pathology and Laboratory Medicine, Children's Mercy Hospital, Kansas City, MO, USA, ou_persistent22              
16Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO, USA, ou_persistent22              
17Pediatric Pathology and Laboratory Medicine, University of Missouri–Kansas City School of Medicine, Kansas City, MO, USA, ou_persistent22              
18Department of Medical Physiology, University Medical Center Utrecht, Utrecht, The Netherlands, ou_persistent22              
19Department of Biomedical Sciences, University Medical Center Utrecht, Utrecht, The Netherlands, ou_persistent22              
20Department of Neuropediatrics, University Medical Center Schleswig-Holstein, Christian Albrechts University, Kiel, Germany, ou_persistent22              
21Department of Physiology and Pharmacology, Tel Aviv University Medical School, Ramat Aviv, Israel, ou_persistent22              
22Department of Neurology, Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, University Hospital, Goethe-University Frankfurt, Frankfurt, Germany, ou_persistent22              
23Division of Genomic Diagnostics, Children’s Hospital of Philadelphia, Philadelphia, PA, USA, ou_persistent22              
24University Medical Center Schleswig-Holstein, Christian Albrechts University, Kiel, Germany, ou_persistent22              
25Epilepsiezentrum Bethel, Krankenhaus Mara, Kinderepileptologie, Bielefeld, Germany, ou_persistent22              
26Department of Pediatric Neurology, Developmental Medicine and Social Pediatrics Dr. von Hauner’s Children’s Hospital, University of Munich, Munich, Germany, ou_persistent22              
27Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany, ou_persistent22              
28Danish Epilepsy Centre, Dianalund, Denmark, ou_persistent22              
29Institute for Regional Health Services, University of Southern Denmark, Odense, Denmark, ou_persistent22              

内容説明

表示:
非表示:
キーワード: -
 要旨: Importance Knowing the range of symptoms seen in patients with a missense or loss-of-function variant in KCNB1 and how these symptoms correlate with the type of variant will help clinicians with diagnosis and prognosis when treating new patients. Objectives To investigate the clinical spectrum associated with KCNB1 variants and the genotype-phenotype correlations. Design, Setting, and Participants This study summarized the clinical and genetic information of patients with a presumed pathogenic variant in KCNB1.Patients were identified in research projects or during clinical testing. Information on patients from previously published articles was collected and authors contacted if feasible. All patients were seen at a clinic at one of the participating institutes because of presumed genetic disorder. They were tested in a clinical setting or included in a research project. Main Outcomes and Measures The genetic variant and its inheritance and information on the patient's symptoms and characteristics in a predefined format. All variants were identified with massive parallel sequencing and confirmed with Sanger sequencing in the patient. Absence of the variant in the parents could be confirmed with Sanger sequencing in all families except one. Results Of 26 patients (10 female, 15 male, 1 unknown; mean age at inclusion, 9.8 years; age range, 2-32 years) with developmental delay, 20 (77%) carried a missense variant in the ion channel domain of KCNB1, with a concentration of variants in region S5 to S6. Three variants that led to premature stops were located in the C-terminal and 3 in the ion channel domain. Twenty-one of 25 patients (84%) had seizures, with 9 patients (36%) starting with epileptic spasms between 3 and 18 months of age. All patients had developmental delay, with 17 (65%) experiencing severe developmental delay; 14 (82%) with severe delay had behavioral problems. The developmental delay was milder in 4 of 6 patients with stop variants and in a patient with a variant in the S2 transmembrane element rather than the S4 to S6 region. Conclusions and Relevance De novo KCNB1 missense variants in the ion channel domain and loss-of-function variants in this domain and the C-terminal likely cause neurodevelopmental disorders with or without seizures. Patients with presumed pathogenic variants in KCNB1 have a variable phenotype. However, the type and position of the variants in the protein are (imperfectly) correlated with the severity of the disorder.

資料詳細

表示:
非表示:
言語: eng - English
 日付: 2017
 出版の状態: 出版
 ページ: -
 出版情報: -
 目次: -
 査読: 査読あり
 識別子(DOI, ISBNなど): DOI: 10.1001/jamaneurol.2017.1714
 学位: -

関連イベント

表示:

訴訟

表示:

Project information

表示:

出版物 1

表示:
非表示:
出版物名: JAMA Neurology
  省略形 : JAMA Neurol
種別: 学術雑誌
 著者・編者:
所属:
出版社, 出版地: Chicago, Ill. : American Medical Association
ページ: - 巻号: 74 (10) 通巻号: - 開始・終了ページ: 1228 - 1236 識別子(ISBN, ISSN, DOIなど): その他: 2168-6157
CoNE: https://pure.mpg.de/cone/journals/resource/2168-6157